Risk of neuropsychiatric and cardiovascular adverse events following treatment with varenicline and nicotine replacement therapy in the UK Clinical Practice Research Datalink:a case-crossover study by Thomas, Kyla H et al.
        
Citation for published version:
Thomas, KH, Davies, NM, Taylor, AE, Taylor, GMJ, Gunnell, D, Martin, RM & Douglas, I 2021, 'Risk of
neuropsychiatric and cardiovascular adverse events following treatment with varenicline and nicotine
replacement therapy in the UK Clinical Practice Research Datalink: a case-crossover study', Addiction, vol. 116,








This is the peer reviewed version of the following article: Thomas, K. H., Davies, N. M., Taylor, A. E., Taylor, G.
M. J., Gunnell, D., Martin, R. M., and Douglas, I. (2020) Risk of neuropsychiatric and cardiovascular adverse
events following treatment with varenicline and nicotine replacement therapy in the UK Clinical Practice
Research Datalink: a casecrossover study. Addiction, , which has been published in final form at
https://doi.org/10.1111/add.15338. This article may be used for non-commercial purposes in accordance with
Wiley Terms and Conditions for Self-Archiving.
University of Bath
Alternative formats
If you require this document in an alternative format, please contact:
openaccess@bath.ac.uk
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 17. Aug. 2021
For Review Only
Risk of neuropsychiatric and cardiovascular adverse events 
following treatment with varenicline and nicotine 
replacement therapy in the UK Clinical Practice Research 
Datalink: a case-crossover study 
Journal: Addiction
Manuscript ID ADD-19-0986.R2
Manuscript Type: Research Report
Date Submitted by the 
Author: n/a
Complete List of Authors: Thomas, Kyla; University of Bristol, Bristol Medical School
Davies, Neil; University of Bristol, Bristol Medical School; Medical 
Research Council Integrative Epidemiology Unit, University of Bristol; 
K.G. Jebsen Center for Genetic Epidemiology,  Department of Public 
Health and Nursing, NTNU, Norwegian University of Science and 
Technology
Taylor, Amy; University of Bristol, Bristol Medical School; University 
Hospitals Bristol NHS Foundation Trust and University of Bristol, National 
Institute for Health Research Bristol Biomedical Research Centre
Taylor, Gemma; University of Bath, Addiction and Mental Health Group 
(AIM), Department of Psychology
Gunnell, David; University of Bristol , Bristol Medical School; University 
Hospitals Bristol NHS Foundation Trust and University of Bristol, National 
Institute for Health Research Bristol Biomedical Research Centre
Martin, Richard; University of Bristol, Bristol Medical School; University 
of Bristol, Medical Research Council Integrative Epidemiology Unit
Douglas, Ian; London School of Hygiene and Tropical Medicine, 
Department of Non-communicable Disease Epidemiology
SUBSTANCE: tobacco
METHOD: cohort/longitudinal studies
FIELD OF STUDY: epidemiology





1 Risk of neuropsychiatric and cardiovascular adverse events following 
2 treatment with varenicline and nicotine replacement therapy in the UK Clinical 
3 Practice Research Datalink: a case-crossover study 
4
5 Authors: 
6 Kyla H Thomas 1, Neil M Davies 1,2,3, Amy E Taylor 1,4, Gemma M J Taylor 5, David 
7 Gunnell 1,4, Richard M Martin 1,2,4, Ian Douglas 6
8 1. Bristol Medical School, Population Health Sciences, Canynge Hall, University of 
9 Bristol, Bristol, BS8 2PS, United Kingdom.
10 2. Medical Research Council Integrative Epidemiology Unit, University of Bristol, 
11 Bristol, BS8 2BN, United Kingdom.
12 3. K.G. Jebsen Center for Genetic Epidemiology, Department of Public Health and 
13 Nursing, NTNU, Norwegian University of Science and Technology, Norway.
14 4. National Institute for Health Research Bristol Biomedical Research Centre, 
15 University Hospitals Bristol NHS Foundation Trust and University of Bristol, United 
16 Kingdom.
17 5. Addiction and Mental Health Group (AIM), Department of Psychology, University 
18 of Bath, Bath, BA2 7AY, United Kingdom.
19 6. Department of Non-communicable Disease Epidemiology, Faculty of 
20 Epidemiology and Population Health, LSHTM, London, WC1E 7HT, United Kingdom. 
21
Page 1 of 43 Addiction
For Review Only
2
22 Corresponding Author: Kyla Thomas, Bristol Medical School, Population Health 
23 Sciences, Canynge Hall, Bristol, BS8 2PS, kyla.thomas@bristol.ac.uk
24
25 Running Head: Safety of varenicline and NRT 
26
27 Words: 5000 (excluding abstract, references, tables, figures). Tables: 2 Figures: 3 
28
29 Competing interests:  All authors have completed the ICMJE uniform disclosure 
30 form at www.icmje.org/coi_disclosure.pdf and declare: KHT received funding for the 
31 project from the Academy of Medical Sciences Starter Grant for Clinical Lecturers 
32 Scheme (supported by the Wellcome Trust, British Heart Foundation, Medical 
33 Research Council, Versus Arthritis, Prostate Cancer UK and the Royal College of 
34 Physicians). AT has received a Global Research Award for Nicotine Dependence 
35 (GRAND), an independently reviewed, competitive grants programme supported by 
36 Pfizer, to the University of Bristol. IJD is supported by an unrestricted grant from 
37 GlaxoSmithKline and holds shares in GlaxoSmithKline. 
38
39 Keywords: varenicline, nicotine replacement therapy, adverse events, observational 








45 Background: Varenicline and nicotine replacement therapy (NRT) are the most 
46 commonly used medications to quit smoking. Given their widespread use, monitoring 
47 adverse risks remains important. 
48 Aims: To estimate the neuropsychiatric and cardiovascular risks associated with 
49 varenicline and NRT as used in routine UK care. 
50 Design: Case crossover study. 
51 Setting: UK based electr nic primary care records in the Clinical Practice Research 
52 Datalink from 2006 to 2015 linked to hospital and mortality datasets.
53 Participants: Adult smokers observed in periods when exposed and not exposed to 
54 either varenicline or NRT. 
55 Measurements: Main outcomes include suicide, self-harm, myocardial infarction 
56 (MI), all-cause and cause-specific death (MI, chronic obstructive pulmonary disease 
57 (COPD)). In primary analyses, conditional logistic regression was used to compare 
58 the chance of varenicline or NRT exposure in the risk period (90 days prior to the 
59 event) with the chance of exposure in an earlier single reference period (91-180 days 
60 prior to the event) or multiple 90-day reference periods to increase statistical power.  
61 Findings: In the primary analyses, findings were inconclusive for the associations 
62 between varenicline and the main outcomes using a single reference period, whilst 
63 NRT was associated with MI (Odds ratio (OR) 1.40, 95% Confidence interval (CI) 
64 1.18 -1.67). Using multiple reference periods, varenicline was associated with an 
65 increased risk of self-harm (OR 1.32, 95% CI 1.12- 1.56) and suicide (OR 3.56, 95% 
66 CI 1.32- 9.60) but a reduction in all-cause death (OR 0.75, 95% CI 0.61-0.93). NRT 
Page 3 of 43 Addiction
For Review Only
4
67 was associated with MI, self-harm, and deaths from MI, COPD and all causes when 
68 using multiple reference periods. 
69 Conclusions
70 The observed associations may not be causal. They may reflect health changes at 
71 the time of smoking cessation (nicotine replacement therapy is prescribed for people 
72 with cardiac problems) or be associated with quit attempts (exposure to both 



















89 Smoking is the leading preventable cause of morbidity and mortality in many 
90 countries. (1, 2) Varenicline, bupropion and nicotine replacement therapy (NRT) are 
91 all licensed as smoking cessation medicines in the UK, however, bupropion is much 
92 less commonly prescribed than the other medications. (3) Varenicline is the most 
93 effective smoking cessation medicine in monotherapy; a network meta-analysis of 
94 randomised controlled trials showed that for every 10 smokers who quit with single 
95 form nicotine replacement therapy (NRT) or bupropion, about 16 would be expected 
96 to quit with varenicline. (4) Consistent findings were reported in a large prospective 
97 cohort study which showed that patients prescribed varenicline were more likely to 
98 be smoking abstinent than those prescribed NRT, an association which persisted for 
99 up to four years. (5)  However, varenicline has not been shown to be more effective 
100 than combination NRT (for example nicotine patch plus a faster acting form of NRT 
101 such as nasal spray, gum or inhalator). (4) 
102
103 Concerns about the cardiovascular and neuropsychiatric safety of varenicline led 
104 regulatory agencies to issue safety warnings about varenicline’s possible adverse 
105 effects. (6, 7)  From 2009 to 2016, the US Food and Drug Administration (FDA) 
106 required that varenicline carry a Black Box warning on its product labelling; this is the 
107 agency’s strongest safety warning. (6) Although the Black Box warning was removed 
108 by the FDA in December 2016, (8) concerns about varenicline persist among some. 
109 Coroners have linked varenicline to several suicides in Australia; the FDA’s decision 
110 to downgrade the safety warning has also been criticised. (9) Concerns have also 
111 been raised previously about the relationship between NRT and serious 
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112 cardiovascular adverse events in older studies (10, 11) These findings have not 
113 been supported by a recent Cochrane review, which found little evidence that NRT 
114 increased the risk of MI, although it increased the odds of chest pains and 
115 palpitations relative to control. (12)
116
117 Various study designs with differing strengths and limitations (13) have been used to 
118 investigate these safety issues, including case reports, observational cohort studies 
119 and meta-analyses. Whereas studies using data from spontaneous reporting 
120 systems have reported an increase in psychiatric adverse effects such as suicide 
121 with varenicline use (14), large observational studies, randomised controlled trials 
122 (RCTs), meta-analyses and network meta-analyses of RCTs have not supported 
123 these findings. (4, 15-24) Additionally, large meta-analyses have provided conflicting 
124 evidence regarding whether patients prescribed varenicline are at increased risk of 
125 adverse cardiovascular events such as myocardial infarction. (25-28) Similarly, there 
126 are conflicting reports regarding the cardiovascular safety of NRT. A meta-analysis 
127 by Mills et al. (2010) found that NRT was associated with an elevated risk of chest 
128 pain and heart palpitations. (29) However, their more recent network meta-analysis 
129 found no evidence that NRT was associated with major adverse cardiovascular 
130 events, although an elevated risk was observed for all cardiovascular events, 
131 including less serious events such as heart palpitations. (28) A 2018 Cochrane 
132 review reported similar findings.(12) 
133
134 There are concerns about the validity of findings using different study designs. First, 
135 although RCTs are considered the gold standard for the evaluation of the intended 
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136 effects of medicines, they are rarely powered or designed to detect rare unintended 
137 adverse effects. Although one of the key aims of meta-analyses is to combine data 
138 from multiple trials and in effect, increase the sample size, the sample size 
139 requirements for rare outcomes, e.g. suicide, may still be prohibitively large. (30) 
140 Second, although observational pharmacoepidemiological studies that utilise large 
141 primary care databases are more likely to meet the sample size requirements for 
142 identifying rare adverse outcomes, they are prone to residual or uncontrolled 
143 confounding, in particular confounding by indication. Confounding by indication may 
144 arise because individuals who are prescribed a particular medication are likely to 
145 differ from those who are not prescribed the drug, because there is a reason or 
146 indication for prescribing a drug. (31) For example, the use of smoking cessation 
147 medicines may appear to be associated with an increased risk of cardiovascular 
148 disease. However, smoking itself is a major risk factor for cardiovascular disease. 
149 One approach to overcoming confounding by indication is to compare rates of 
150 adverse events in patients prescribed different drugs to treat the same underlying 
151 condition (i.e. use of active comparators). (32) 
152
153 Epidemiological study designs which rely only on cases, known as case-only 
154 designs, are increasingly used to avoid pitfalls such as confounding and selection 
155 bias which may occur in observational studies with control groups such as cohort 
156 and case-control studies.(33)  Case only designs (which include the case-crossover 
157 method, case time control method and self-controlled case series), may benefit from 
158 the elimination of time invariant within-person confounding factors such as socio-
159 economic position and genetic predisposition. Other benefits include having greater 
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160 statistical power to detect rare adverse effects and being less costly to carry out 
161 compared with conventional observational studies. (33) 
162
163 In the current study, we estimate the neuropsychiatric and cardiovascular adverse 
164 risks of varenicline and NRT in the UK Clinical Practice Research Datalink (CPRD) 
165 using a case-crossover study design.
166
167 METHODS
168 Study design and patients
169 The CPRD is one of the largest primary care databases in the world and contains 
170 electronic medical records from >15 million individuals, who are representative of the 
171 UK population. (34) In the UK >98% of the population are registered with a general 
172 practitioner (GP), who act as gatekeepers of care for the National Health Service. 
173 Data from GP consultations as well as information which is fed-back from secondary 
174 care referrals are routinely entered onto computers, creating the electronic medical 
175 records which the CPRD is comprised of. We used data from the CPRD and linked 
176 hospital admissions data from the Hospital Episode Statistics (HES) database and 
177 mortality data from the Office of National Statistics (ONS) mortality dataset to 
178 conduct a population-based case-crossover study. The case-crossover method is a 
179 type of case-only design which is epidemiologically and statistically comparable to 
180 matched case-control analyses except the case serves as his/her own control. (35-
181 37) In the simplest design, study participants are compared at two different time 
182 points (see Figure 1), the first time point is nearer to the occurrence of the event of 
183 interest (referred to as the risk period); the second time point represents a similar 
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184 time interval occurring further away from and earlier than the event of interest 
185 (referred to as the reference period). Therefore, if a particular treatment were 
186 actually associated with a specific outcome, it would be expected that exposure to 
187 that treatment would occur more frequently in the risk period than the reference 
188 period. The similarity of the case-crossover study to the matched case-control design 
189 occurs as only discordant pairs (i.e. those exposed in the risk period but not in the 
190 reference period and vice versa) contribute to the statistical analysis. Individuals with 
191 concordant matched pairs (i.e. exposed or unexposed to treatment in both time 
192 periods) are uninformative. 
193 All hypotheses and analyses (with the exception of the analyses exploring time 
194 dependent confounding) were pre-specified in a study protocol which was approved 
195 by the Independent Scientific Advisory Committee (ISAC), available from 
196 http://research-information.bristol.ac.uk/en/persons/kyla-h-thomas(e3917519-6a48-
197 4192-af81-a1199d545b40)/projects.html (Accessed 18th March 2020). We used the 
198 most recent version of CPRD Gold available at the time (November 2015). 
199
200 Participants
201 Patients were included if they were adult smokers from 1st September 2006 (when 
202 varenicline was licensed in the UK) onwards to 31st November 2015. Smokers were 
203 defined as patients who have a smoking record which indicates current smoker 
204 (obtained from the “Additional Clinical Details” file in the CPRD) or Read codes 
205 which indicate current smoking after the 1st September 2006. Read codes are a 
206 coded thesaurus of clinical terms which are used in electronic health care records in 
207 the UK National Health Service. Read code algorithms to define smoking status were 
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208 based on those used in a previous study by Szatkowski and McNeill (2013) in The 
209 Health Improvement Network (THIN) database, which is similar to the CPRD. (38) 
210 The prevalence of current smoking identified from primary care electronic health 
211 records has previously been shown to accurately reflect the prevalence reported in 
212 national surveys such as the Health Survey for England. (39)
213
214 Records from patients classified as ‘acceptable’ by the CPRD from all up-to-
215 standard practices at least 18 months prior to date of entry of each cohort (1st 
216 January 2005) were included. Patient data were defined as “acceptable” by the 
217 CPRD if they met minimum quality control standards, for example they had 
218 information on sex, date of birth and first registration with no breaks in registration, 
219 i.e. a valid GP registration period. Up-to-standard practices included those which 
220 reported when their patients first registered with the practice and left the practice, 
221 with continuous data reporting in between. 
222
223 Patients were excluded if they were registered at a GP practice for less than 365 
224 days before the first recorded prescription. We excluded patients prescribed both 
225 NRT and varenicline at the same time. In a previous CPRD analysis, this occurred 
226 for 0.25% of all prescriptions.(18) 
227
228 Exposures, outcomes and covariates
229 Cases included smokers who had experienced one of the following smoking-related 
230 outcomes: suicide, non-fatal self-harm (suicide attempt), myocardial infarction (MI) 
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231 and death from all causes and the following specific causes- MI, lung cancer and 
232 chronic obstructive pulmonary disease (COPD) (the latter were included as major 
233 causes of smoking related morbidity and mortality).  CPRD Read codes were used to 
234 identify self-harm and MI using validated algorithms. (40, 41) HES data were used to 
235 identify inpatient hospital admissions for self-harm. Deaths were identified using ONS 
236 mortality data. We used linked ONS mortality data to identify MI deaths as previous 
237 research has shown that failure to do so may result in biased estimates of MI incidence 
238 and outcome. (41) Similarly, CPRD recording of suicide has also been shown to be 
239 unreliable although the under-reporting of self-harm is less marked. (40) The following 
240 International Classification of Disease Tenth Revision (ICD-10) codes were used for 
241 mortality: MI (codes I21-I22), COPD (codes J40-J44), lung cancer (C34, C78, D02.2, 
242 D14.3, D38.1), suicide (intentional self-harm, codes X60-X84 and events of 
243 undetermined attempt, codes Y10-Y34). In England and Wales, the Office for National 
244 Statistics definition of suicides includes deaths given an underlying cause of intentional 
245 self-harm in addition to deaths caused by injury or poisoning where the intent was 
246 undetermined for those aged 15 and over. This is because most undetermined deaths 
247 are likely to be suicides. (42) Inpatient self-harm admissions were identified using the 
248 same ICD-10 codes that were used to identify suicide deaths. Only incident events 
249 were included in the statistical analysis. Events were assumed to be independent. 
250
251 Exposure to varenicline or NRT in the CPRD was identified using product codes. A 
252 product code is a unique code in the CPRD which is used to identify each specific 
253 prescribed medicine selected by a GP for treatment. Product codes are available from 
254 the “Therapy file” of the CPRD. 





257 Primary analysis 
258 For the primary analysis, the risk period was defined as 90 days prior to a specific 
259 outcome, while the reference period was defined as 91 to 180 days prior to the 
260 outcome. A time period of 90 days was chosen as the risk period as the maximum 
261 recommended treatment duration for varenicline is 12 weeks (3 months) 
262 (https://bnf.nice.org.uk/drug/varenicline.html last accessed 18th March 2020). NRT 
263 treatment for smoking cessation should also continue for up to 3 months before dose 
264 reduction (https://bnf.nice.org.uk/drug/nicotine.html#indicationsAndDoses last 
265 accessed 18th March 2020). If a study participant was exposed to a particular 
266 smoking cessation medicine for at least one day in a given reference period or risk 
267 period, the person was considered exposed to that medicine for the entire duration of 
268 that period. All analyses were repeated replacing exposure to varenicline with 
269 exposure to NRT. NRT was used as a comparator as its mechanism of action is 
270 different from varenicline; the association of both medicines with a specific adverse 
271 event could therefore imply the event was associated with the timing of smoking 
272 cessation instead of a causal effect of the medication. Whilst the case-crossover 
273 method deals with time invariant confounding, time varying confounding remains a 
274 problem which this approach could potentially address indirectly. 
275
276 Each study participant formed two halves of a matched pair, comparing exposure to 
277 varenicline in the risk period (90 days prior to the outcome event) with exposure to 
278 varenicline in a single reference period (90 days before the risk period). Conditional 
Page 12 of 43Addiction
For Review Only
13
279 logistic regression was used to calculate odds ratios (ORs) and 95% confidence 
280 intervals (CIs) for the discordant matched pairs using the clogit command. 
281 Analyses were carried out using Stata statistical software version 14MP. 
282
283 Secondary (Sensitivity) analyses 
284 Sensitivity analyses were repeated with 30 days and 180 days prior to the event as 
285 the risk period such that the reference periods were 31-60 days prior to the event 
286 and 181-360 days prior to the event. 
287
288 Multiple reference periods 
289 Multiple reference periods were used to increase the statistical power of the primary 
290 and secondary analyses. This involved using up to a maximum of four reference 
291 periods compared to one risk period. For example, in the primary analysis, exposure 
292 to varenicline in the risk period (90 days prior to the event) was compared with 
293 exposure to varenicline in four 90-day reference periods (i.e. 91-180 days prior to the 
294 event, 181-270 days prior to the event, 271-360 days prior to the event and 361-450 
295 days prior to the event). 
296
297 Assessment of time dependent confounding 
298 Case-crossover designs assume no unmeasured time dependent confounding. We 
299 investigated the possibility of time-dependent confounding in a post-hoc exploratory 
300 analysis by estimating the rates of four events: primary care diagnoses and 
301 hospitalisation for myocardial infarction and self-harm. Primary care diagnoses were 
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302 identified using Read codes in the CPRD. Hospital admissions were identified using 
303 the linked hospital admissions dataset using the previously described ICD-10 codes 
304 for self-harm and MI. We did this by extracting the weekly number of records 
305 indicating each of the four events in the year before and the year after the patients 
306 were prescribed any NRT or varenicline prescription. This means there are multiple 
307 prescriptions per person and the denominator for this analysis is all NRT or 
308 varenicline prescriptions. We set week zero to be the week before the index 
309 prescription. We then plotted the event rate by dividing the number of events per 
310 week by the number of NRT and varenicline prescriptions.
311
312 RESULTS
313 The baseline characteristics (median age and sex) of participants experiencing 
314 events (excluding lung cancer) are shown in Table 1. A flowchart of the number of 
315 patients and prescriptions assessed for eligibility and the reasons for exclusion is 
316 presented in Figure S1. The number of events for each outcome is shown in Table 2.   
317 Lung cancer deaths were excluded from further analysis due to the very small 
318 number of events identified. For the majority of patients dying from lung cancer, NRT 
319 was not prescribed in either the risk or the reference period; for varenicline this was 
320 the case for all lung cancer deaths.  NRT was prescribed in the reference period but 
321 not the risk period for <5 lung cancer deaths. 
322
323 Table 2 also shows the association between adverse events in smokers and 
324 exposure to varenicline or NRT using 90-day risk, and up to a maximum of four 
325 reference periods. 




327 Single reference period
328 For a single 90-day risk period compared to the immediately preceding 90-day 
329 reference period, there was inconclusive evidence that varenicline was associated 
330 with an increased risk of self-harm (OR 1.07, 95% CI 0.85 -1.35); whilst the risk of 
331 suicide was elevated, estimates were imprecise and confidence intervals spanned 
332 the null value (OR 3.50, 95% CI 0.73 - 16.85). There was inconclusive evidence of 
333 an association between varenicline and self-harm hospital admissions (OR 0.86, 
334 95% CI 0.61-1.23), deaths from MI (OR 0.80, 95% CI 0.32-2.03), or COPD (OR 0.92, 
335 95% CI 0.53-1.61]). There was a positive association between NRT and MI (OR 
336 1.40, 95% CI 1.18-1.67), with inconclusive evidence for other outcomes.   
337
338 Multiple reference periods 
339 When multiple 90-day reference periods were used with a single 90-day risk period 
340 to increase statistical power, there was evidence that varenicline was associated 
341 with an increased risk of self-harm (OR 1.32, 95% CI 1.12-1.56) and a more than 
342 threefold increased risk of suicide (OR 3.56, 95% CI 1.32-9.60). However, 
343 varenicline was associated with a reduction in deaths from all causes (OR 0.75, 95% 
344 CI 0.61-0.93). NRT was associated with an increased risk of MI (OR 1.54, 95% CI 
345 1.36-1.74), self-harm (OR 1.30, 95% CI 1.18-1.44), MI deaths (OR 1.53, 95% CI 
346 1.11-2.10), COPD deaths (OR 1.33, 95% CI 1.14-1.56) and all-cause deaths (OR 
347 1.28, 95% CI 1.18-1.40). There was inconclusive evidence for an association of NRT 
348 with suicide (OR 1.32, 95% CI 0.69-2.53) or self-harm hospital admissions (OR 1.08, 
349 95% CI 0.92-1.26).  





352 Secondary (sensitivity) analyses using 30-day and 180-day risk and reference 
353 periods are shown in Table S2 and Table S3 respectively and were largely 
354 consistent with the findings of the multiple reference period analyses. Using a 30-day 
355 risk and reference period, varenicline was associated with a reduced risk of all-cause 
356 mortality. NRT was associated with an increased risk of MI. For the 180-day risk and 
357 reference periods, varenicline was associated with a reduction in all-cause mortality 
358 and COPD deaths and an increased risk of MI, self-harm and inpatient self-harm 
359 admissions (using multiple reference periods only). NRT was associated with an 
360 increased risk of MI and self-harm. However, NRT was also associated with an 
361 increase in MI deaths and all-cause mortality (using multiple reference periods).
362
363 Figure 2 illustrates the rate of primary care diagnoses of and hospital admissions for 
364 myocardial infarction in the 52 weeks before and after varenicline and NRT 
365 prescriptions. Negative values on the x-axis indicate the weeks before the 
366 prescription, positive values indicate the weeks after the prescription. There was a 
367 significant increase in the number of diagnoses of MI events in the weeks leading up 
368 to a NRT prescription (from 1.2 MI events per 1000 prescriptions 52 weeks before 
369 being prescribed NRT to 15.7 events per 1000 prescriptions in the week before 
370 being prescribed NRT), followed by a very substantial fall in the number of diagnoses 
371 in the weeks following a prescription (from 14.1 events per 1000 in the week of being 
372 prescribed NRT to between 1 and 1.5 events per 1000 from the 4th week after being 
373 prescribed NRT onwards). The results were similar for the relationship between 
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374 hospital admissions for myocardial infarction and NRT prescribing. A similar 
375 temporal trend was observed with varenicline prescriptions, although it was much 
376 less marked. These findings may be due to non-fatal cardiovascular events or 
377 symptoms triggering prescriptions; in our analyses prescription of a smoking 
378 cessation product is likely to be affected by within individual time dependent 
379 confounding. 
380
381 Figure 3 illustrates the event rates per 1000 prescriptions for primary care diagnosis 
382 and hospital admissions for self-harm. There were much smaller changes in the 
383 event rate per 1000 prescriptions for self-harm events compared with MI events over 
384 time. Overall, there were small changes in the self-harm event rates before and after 
385 NRT prescriptions were issued (event rates were consistently between 0.6 and 0.7 
386 per 1000 prescriptions). However, self-harm events per 1000 prescriptions were 
387 markedly lower in the weeks before a varenicline prescription (0.1 to 0.2 events per 
388 1000) compared with the weeks following a varenicline prescription (0.3 to 0.6 
389 events per 1000), showing that varenicline was less likely to be issued if the patient 
390 had a recent primary care diagnosis of self-harm, consistent with prescribing 




395 In the primary analysis using a single 90-day risk period and reference period we 
396 found inconclusive evidence that varenicline increased the risk of any of our 
397 outcomes of interest. Although NRT was associated with a 40% (95% CI 18% to 
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398 67%) increased risk of MI, there was strong evidence of time dependent confounding 
399 suggesting that MI (or heart disease more generally) may lead to the prescription of 
400 NRT. Findings were also sensitive to design decisions. When multiple 90-day 
401 reference periods were used to increase statistical power, varenicline was 
402 associated with a 256% (95% CI 32% to 860%) increased risk of suicide, 32% 
403 increased risk of self-harm and a 25% reduction in all-cause mortality. Similarly, NRT 
404 was associated with an increased risk of self-harm and deaths from all-causes, MI 
405 and COPD. There was inconclusive evidence of an increased risk of self-harm 
406 hospital admissions with varenicline or NRT. In the secondary analyses, varenicline 
407 was associated with a reduction in all-cause deaths using the shorter 30-day time 
408 window for the risk and reference periods and NRT was associated with an 
409 increased risk of MI. However, using multiple reference periods and the 180-day risk 
410 and reference periods, positive associations were observed for MI and self-harm 
411 (varenicline and NRT), self-harm hospital admissions (varenicline only) and deaths 
412 from MI and all causes (NRT only). 
413
414 Strengths and Limitations
415 The use of data from the CPRD is one of the main strengths of this study. Study 
416 participants are likely to be more representative of patients prescribed smoking 
417 cessation medicines in the UK compared with the highly selected patients usually 
418 included in randomised controlled trials. Second, we used validated code lists and 
419 linked datasets to improve the accuracy of detection of our outcomes of interest. (40, 
420 41) Third, we used the case-crossover method to investigate the association of 
421 varenicline and NRT with adverse outcomes. Advantages of this study design 
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422 include its ability to completely control for between person confounding, minimising 
423 within-person time invariant confounding factors (i.e. subject characteristics that 
424 remain constant) and statistical efficiency (the use of multiple reference periods for 
425 one risk period increases statistical power). (35) Also, as we investigated varenicline 
426 as well as NRT, we could assess whether events may have resulted from nicotine 
427 withdrawal (e.g. the increased risk of self-harm events observed with both treatments 
428 during the 90-day risk and reference period when multiple reference periods were 
429 used). 
430
431 A major study limitation is the observational study design. Therefore, the analysis 
432 was still prone to residual time variant confounding, in particular within person 
433 confounding by transient factors for example changes in disease severity or 
434 comorbid conditions. (37) The result of within person comparisons would also be 
435 affected by the choice of comparison periods. We observed strong time-dependent 
436 confounding, shown by the temporal patterns in the occurrence of MI and self-harm 
437 related events before and after smoking cessation medication prescribing in the 
438 exploratory analyses. Patients were more likely to be prescribed NRT following a 
439 primary care diagnosis of MI and hospitalisation for MI. Patients prescribed 
440 varenicline were less likely to have had a primary care diagnosis or hospital 
441 admission for self-harm in the weeks prior to the prescription. This may be because 
442 GPs were less likely to prescribe varenicline to patients who have recently self-
443 harmed. Although we observed an association between both varenicline and NRT 
444 and self-harm events in our primary analyses using multiple reference periods, we 
445 did not find evidence of any associations with self-harm hospitalisations. This may 
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446 have been caused by a lack of statistical power as we identified half as many self-
447 harm hospitalisations as self-harm events. 
448
449 We were unable to perform case time control analyses as stated in our original 
450 protocol as we could not obtain a sufficient number of matched controls. This would 
451 have allowed statistical adjustments to be made for a common time trend such as a 
452 change in the prescribing pattern of the smoking cessation medicines. (37) However, 
453 this is unlikely to be an issue in the short time periods utilised in the main analyses. It 
454 is important to note that our analyses were also sensitive to some of our design 
455 decisions, for example the number of matching periods and the duration of the risk 
456 and reference periods. In the primary analysis, the use of multiple reference periods 
457 provided a point estimate in a more harmful direction to the result using a single 
458 reference period for MI and self-harm hospital admissions in the varenicline group. 
459 Additionally, for both varenicline and NRT, increases in the length of the risk and 
460 reference periods from 30 days to 180 days resulted in a greater number of positive 
461 associations using multiple reference periods. This may be indicative of a temporal 
462 bias which was not fully accounted for in the analyses, i.e. with increasing time from 
463 the event occurrence, the potential for time dependent confounding increases due to 
464 changes in the individual such as changes in health status. This is suggested by the 
465 strong temporal pattern of event rates we observed around the time smoking 
466 cessation medication was started.
467
468 Our analyses were also restricted to products prescribed in primary care (thus 
469 excluding patients receiving smoking cessation products in smoking cessation clinics 
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470 or buying over the counter NRT from pharmacies). Those who visit a healthcare 
471 professional for prescribed medications are likely to be sicker and to be less affluent 
472 or of a lower socioeconomic position compared to those buying over the counter 
473 medicines. (43) Therefore, the analyses may not be generalisable to the wider 
474 population of people taking smoking cessation medicines including those obtained 
475 over the counter without a prescription. Additionally, being prescribed medication 
476 does not mean that the patient actually took the medication. We had no information 
477 on treatment compliance or adherence but problems with either would tend to bias 
478 results towards a null effect. 
479
480 Comparison with other case only studies
481 Three recent studies have used within person designs to investigate the 
482 neuropsychiatric and cardiovascular safety of varenicline. (44-46) Monarrez- Espino 
483 et al. (2018) carried out a case-crossover study using data from Swedish health and 
484 administrative registers. (44)  They reported on four different hazard (risk) periods, 
485 including a hazard period of 1-84 days, which approximates to our main analyses 
486 using a 90-day risk and reference period. There was inconclusive evidence that 
487 varenicline was associated with MI (OR 0.98, 95% CI 0.80-1.22), suicide (OR 0.58, 
488 95% CI 0.32-1.06) or suicide attempt (OR 0.82, 95% CI 0.63-1.07). However, 
489 varenicline was associated with a reduction in the outcome which combined suicide 
490 and suicide attempt (OR 0.77, 95% CI 0.60-0.98). These findings are not consistent 
491 with our study, possibly due to differences in the study populations or differences in 
492 prescribing behaviour for smoking cessation in Sweden compared with the UK, 
493 leading to different temporally associated changes in risk. Gershon et al. (2018) used 
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494 a self-controlled risk interval study design to investigate neuropsychiatric and 
495 cardiovascular hospitalisations with varenicline. (45) Similar to the case-crossover 
496 study, each patient acts as his/her own control, minimising within-person time 
497 invariant confounding. However, it differs from the case-crossover study design as 
498 for patients exposed to a particular treatment, it examines the risk of the outcome of 
499 interest in a specified period closest to the exposure (risk period) with a remaining 
500 observation period (control period). For new users of varenicline, the authors found a 
501 34% higher incidence of cardiovascular events in the 12-week risk period compared 
502 with the control interval (relative incidence 1.34, 95% CI 1.25-1.44). An increase in 
503 the incidence of neuropsychiatric events was also observed for varenicline (relative 
504 incidence 1.06, 95% CI 1.00-1.13). This finding is similar to our finding for the 
505 association of varenicline and self-harm in the main analyses (OR 1.07, 95% CI 
506 0.85-1.35). The differences in the results for cardiovascular outcomes may be due to 
507 the differences in estimation of the risk periods and population size. The authors did 
508 not examine outcomes in relation to NRT. 
509 Molero et al. (2015) used a within-person comparison cohort design to examine 
510 associations between varenicline and a range of outcomes including new psychiatric 
511 conditions and suicidal behaviour.(46) Although varenicline was not shown to be 
512 associated with suicidal behaviour (hazard ratio 1.00, 95% CI 0.72-1.37), it was 
513 associated with an increase in the risk of anxiety conditions (hazard ratio 1.27, 95% 
514 CI 1.06-1.51) and mood conditions (hazard ratio 1.28, 95% CI 1.07-1.52). Suicidal 
515 behaviour was defined as emergency inpatient or outpatient hospital visits or death 
516 due to intentional self-harm and differed from our analyses as they did not include 
517 ICD codes for undetermined events or deaths. 
518
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519 One study examined the use of NRT and the risk of acute MI, stroke and death in the 
520 The Health Improvement Network (THIN), using the self-controlled case series 
521 method. (47)  The incidence of MI increased in the 56 days prior to the first 
522 prescription of NRT (incidence ratio 5.55, 95% CI 4.42 to 6.98) although it was not 
523 increased in the 56 days following the first NRT prescription (incidence ratio 1.27, 
524 95% CI 0.82 to 1.97). However, there was an increased risk of MI in the first 14 days 
525 following NRT prescription (incidence ratio 2.39, 95% CI 1.28 to 4.48) which is 
526 consistent with our findings. 
527
528 Comparison with other study designs
529 With respect to neuropsychiatric outcomes, our results from the primary analyses 
530 using a single 90-day risk period and multiple 90-day reference periods are 
531 consistent with prescription event monitoring studies and studies using adverse 
532 event reporting databases, which have reported an increased risk of reported 
533 suicidal behaviour for varenicline compared with NRT.(14, 48-51) However, previous 
534 studies which included comparison groups (i.e. RCTs, meta-analyses of RCTs and 
535 other observational study designs) have reported inconclusive findings as to whether 
536 varenicline is associated with an increased risk of suicide, suicide attempt or other 
537 mental disorders (depression, neurotic disorders or prescriptions for anti-
538 depressants). (15-22) This could partly be because most RCTs and meta-analyses 
539 of RCTs would not have sufficient statistical power to detect an effect of prescribing 
540 varenicline on such a rare outcome. (19, 21) For example, the large EAGLES study 
541 found no significant increase in neuropsychiatric events with varenicline compared to 
542 placebo or NRT. (21) The study had a sample size of 8144 participants across four 
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543 treatment groups; it was statistically powered to detect an adverse event which 
544 occurred in at least 4% of patients in any treatment group (a moderate effect size).  
545 However, a sample size of 21,584 would be needed for a clinical trial to detect the 
546 more than threefold increase we observed for suicide in this study, based on a 
547 suicide incidence rate of 9.2 per 100,000 at 80% power and 5% significance. 
548 Previous meta-analyses of neuropsychiatric events have included <12,000 
549 participants and reported very few suicides; therefore the lack of statistical power to 
550 detect an effect would also be an issue in these studies. (19, 23) Previous 
551 observational cohort studies which found inconclusive evidence between smoking 
552 cessation medicines and neuropsychiatric outcomes or a negative association were 
553 also likely to be impacted by residual confounding (those prescribed varenicline were 
554 healthier than those prescribed NRT) and/or the very limited numbers of suicides 
555 identified (<10). (15, 18, 20, 24) Our study found an association between self-harm 
556 and being prescribed NRT or varenicline which may be explained by an association 
557 between quit attempts and self-harm. Although nicotine withdrawal is known to be 
558 associated with mood changes (52), evidence showing a clear association with self-
559 harm is lacking.
560
561 Our findings for all-cause mortality suggest caution is needed when interpreting 
562 results.  Varenicline was associated with a reduction in all-cause mortality, consistent 
563 with findings using conventional methods of analyses (multivariable regression and 
564 propensity score matching) from previous UK primary care observational studies 
565 using the CPRD and the Q Research database. (18, 20)  The protective effect of 
566 varenicline on all-cause mortality was not driven solely by a reduction in COPD or MI 
567 deaths. However, we were unable to identify the specific causes behind this 
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568 protective effect as our CPRD extract did not include causes of death we had not 
569 prespecified in our protocol. Conversely, we found that NRT was associated with 
570 higher all-cause mortality in our primary analyses using a single 90-day risk period 
571 and multiple 90-day reference periods. However, it is possible that all of the analyses 
572 may have been affected by time dependent residual confounding. Additionally, 
573 previous studies have shown that people prescribed varenicline are likely to be 
574 healthier than those prescribed NRT(15, 18, 20) . 
575
576 Findings regarding the cardiovascular safety of varenicline are also conflicting. In this 
577 study, varenicline was only associated with an increased risk of MI events for the 
578 180-day risk and reference period using multiple reference periods. Although a 19% 
579 increased risk of MI events was observed in the 90-day risk and reference period, 
580 the 95% CI included the null. Previous studies (including the EAGLES study and its 
581 nontreatment extension, (53) meta-analyses of RCTs (26, 28) and an observational 
582 study (20)) found no increase in cardiovascular events with varenicline or NRT. 
583 However, a systematic review of varenicline versus placebo found evidence of an 
584 increased risk. (25) The Mills et al. (2014) network meta-analysis also found an 
585 elevated risk of cardiovascular events associated with NRT, mostly due to less 
586 serious events, but was underpowered to assess the risk of serious events. (28) A 
587 recent cohort study using the CPRD also found an increase in cardiovascular events 
588 by 52 weeks for patients prescribed NRT compared with those receiving smoking 
589 cessation advice only. (54) These findings are consistent with our study. This 
590 association may be due to smokers who experience worsening of symptoms such as 
591 chest pain being more likely to seek help from their GPs to quit smoking (as shown 
592 by Figure 2). 





595 In this study, we used a case-crossover study design to investigate the risk of 
596 neuropsychiatric and cardiovascular outcomes associated with varenicline and NRT 
597 in a real-world setting. For primary analyses using a 90-day risk period and multiple 
598 reference periods, we observed associations between varenicline and suicide and 
599 self-harm as well as associations between NRT and self-harm, MI, MI deaths and all-
600 cause mortality. However, these temporal associations may not be causal, as we 
601 also found strong evidence of time dependent confounding, particularly for our NRT 
602 analyses where those experiencing MI were likely to be prescribed NRT in the week 
603 before the event. The evidence was much less marked for varenicline. The 
604 association of both varenicline and NRT with self-harm in our study may reflect an 
605 association between self-harm and quit attempts, rather than a causal association 
606 with the smoking cessation medications. Additionally, associations such as a 
607 reduction in all-cause mortality with varenicline and an increased risk of COPD 
608 deaths with NRT may be explained by differences in GP prescribing behaviour 
609 (healthier patients are prescribed varenicline) or changes in health status (for 
610 example COPD exacerbation triggering NRT prescribing).  Further evidence will be 
611 provided when the results of the largest network meta-analysis of smoking cessation 
612 medicines and e-cigarettes are reported. (55)  The study will report on smoking 
613 abstinence in addition to safety outcomes including serious adverse events, major 
614 adverse neuropsychiatric events (including suicide and self-harm) and major adverse 
615 cardiovascular events. Further research can aim to replicate our study using similar 
616 datasets, for example Scandinavian record linkage studies and large North American 
617 health care databases. Additionally, mendelian randomisation and genetic 
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618 correlation studies may provide further information on associations with self-harm.  
619 What is clear, is that regardless of cause, people attempting to stop smoking with 
620 smoking cessation therapies appear to have a higher risk of neuropsychiatric and 
621 cardiorespiratory events which may be due to time dependent confounding (people 
622 who are sicker seeking treatment), or theoretically an effect of taking smoking 
623 cessation therapy. More research is needed to elucidate these relationships. 
624
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875 Figure 1 Case-crossover analysis illustrating risk and reference periods and 




880 Legend: ‘X’ represents exposure to a particular treatment. Concordance occurs where there is 
881 exposure to treatment in both periods or exposure in neither periods. Discordance occurs where 
882 there is exposure to treatment in the risk period but not the reference period or exposure in the 
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894 Figure 2- Rate of MI events and hospital admissions per 1000 prescriptions in 
895 the weeks before and after being prescribed varenicline or NRT 
896
897
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898 Figure 3- Rate of self-harm events and hospital admissions per 1000 
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903 Table 1. Baseline characteristics of the cases included in the analyses (people 
904 experiencing events).



















All 19,664 3,461 25,455 12,584 679 8,730 51,786
% female 30.9 36.4 55.5 54.7 25 44.8 44.2
Median age 
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916 Table 2. Odds ratios and 95% confidence intervals of exposure to Varenicline 
917 and NRT using 90-day risk and reference periods for specific adverse events.
      














OR (95% CI) 1:1 
matching
OR (95% CI) 1:4* 
matching
Varenicline  
MI events 19,664 96 113 0.85 (0.65-1.12) 1.19 (0.98-1.45)
Self-Harm events 25,455 151 141 1.07 (0.85-1.35) 1.32 (1.12-1.56)
Self-Harm hospital admissions 12,584 57 66 0.86 (0.61-1.23) 1.08 (0.83-1.42)
MI deaths 3,461 8 10 0.80 (0.32-2.03) 0.82 (0.44-1.66)
Suicide deaths 679 7 2 3.50 (0.73-16.85) 3.56 (1.32-9.60)
COPD deaths 8,730 24 26 0.92 (0.53-1.61) 0.92 (0.64-1.37)
All cause deaths 51,786 84 105 0.80 (0.60-1.07) 0.75 (0.61-0.93)
NRT  
MI events 19,664 303 216 1.40 (1.18-1.67) 1.54 (1.36-1.74)
Self-harm events 25,455 433 414 1.04 (0.91-1.20) 1.30 (1.18-1.44)
Self-harm hospital admissions 12,584 155 183 0.85 (0.68-1.05) 1.08 (0.92-1.26)
MI deaths 3,461 36 32 1.13 (0.70-1.81) 1.53 (1.11-2.10)
Suicide deaths 679 11 7 1.57 (0.61-4.05) 1.32 (0.69-2.53)
COPD deaths 8,730 155 146 1.06 (0.85-1.34) 1.33 (1.14-1.56)
All cause deaths 51,786 556 533 1.04 (0.93-1.18) 1.28 (1.18-1.40)
      
918 *Matching on a maximum of four 90-day reference (ref) periods to increase statistical power. Non-null findings 
919 are bolded.
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